https://allsci.com/news/clinical-trials/acoramidis-attr-cm-cardiac-reverses-damage-in/ AllScien 2026-09-01T09:57:34.388242Z Acoramidis shows signs of cardiac remodeling reversal in ATTR-CM CMR analysis https://allsci.com/news/approvals/mimrylo-fda-approval-polycythemia-vera-approves/ AllScien 2026-09-01T09:09:54.326999Z FDA approves Takeda's Mimrylo as first hepcidin mimetic for polycythemia vera https://allsci.com/news/clinical-trials/vutrisiran-tafamidis-attr-cm-maintains-mortality/ AllScien 2026-09-01T08:59:31.210996Z Vutrisiran shows consistent HELIOS-B benefit regardless of tafamidis use https://allsci.com/news/clinical-trials/mavacamten-obstructive-hypertrophic-cardiomyopathy/ AllScien 2026-09-01T08:54:07.672499Z Five-year Camzyos data show sustained oHCM benefit as aficamten competition emerges https://allsci.com/news/clinical-trials/cardiac-amyloidosis-pet-tracer-bayers-meets-dual/ AllScien 2026-09-01T08:08:30.817064Z Bayer’s evuzamitide posts 94% sensitivity in Phase III cardiac amyloidosis study https://allsci.com/news/licensing-and-partnerships/leios-10xb-101-licensing-agreement-licenses-to/ AllScien 2026-09-01T07:56:19.702014Z Leios hands Greater China rights to Phase III fat reduction drug to CMS https://allsci.com/news/licensing-and-partnerships/opti-mab-platform-antibody-aax-biotech-advances/ AllScien 2026-09-01T07:49:17.330018Z Daiichi Sankyo advances AAX Biotech’s Opti-mAb into antibody program https://allsci.com/news/patents-ip/biomarin-ascendis-patent-settlement-secures/ AllScien 2026-08-31T07:31:26.641182Z BioMarin lands 20% Yuviwel royalty in Ascendis patent settlement https://allsci.com/news/licensing-and-partnerships/flu-vaccine-collaboration-osivax-and-gc-biopharma/ AllScien 2026-08-31T07:13:29.354821Z Osivax and GC Biopharma combine T-cell and antibody approaches in single-shot flu vaccine https://allsci.com/news/approvals/lisraya-dermatomyositis-fda-approval-approves-as/ AllScien 2026-08-31T07:11:25.162217Z FDA approves Lisraya as first targeted therapy for dermatomyositis https://allsci.com/news/approvals/fgfr2-intrahepatic-cholangiocarcinoma-approval/ AllScien 2026-08-31T07:09:05.024635Z HutchMed’s Atled wins China approval for FGFR2-driven bile duct cancer https://allsci.com/news/funding/samsung-biologics-polypeptide-acquisition-1/ AllScien 2026-08-31T07:03:09.860151Z Samsung Biologics raises USD 2.2b to fund PolyPeptide acquisition and capacity expansion https://allsci.com/news/approvals/comirnaty-xfg-fda-approval-approves-pfizer-and/ AllScien 2026-08-31T07:01:10.976342Z Pfizer and BioNTech's XFG-adapted Comirnaty given FDA clearance for fall 2026 rollout